Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Browne, S. Koury, S. Marion, G. Wilding, P. Muti, M. Trevisan (2007)
Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay.Clinical chemistry, 53 2
Alan Lopez, C. Mathers, M. Ezzati, D. Jamison, C. Murray (2006)
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health dataThe Lancet, 367
Carroll Cross, A. Vliet, C. O'Neill, Sam Louie, Barry Halliwell (1994)
Oxidants, antioxidants, and respiratory tract lining fluids.Environmental Health Perspectives, 102
J. Židzik, E. Slabá, P. Joppa, Z. Kluchová, Z. Dorková, P. Skyba, V. Habalová, J. Šalagovič, R. Tkacova (2008)
Glutathione S-transferase and microsomal epoxide hydrolase gene polymorphisms and risk of chronic obstructive pulmonary disease in Slovak population.Croatian medical journal, 49 2
E. Nishio, Yasuhiro Watanabe (1997)
Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols.Biochemical and biophysical research communications, 236 2
Christopher Smith, D. Harrison (1997)
Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysemaThe Lancet, 350
C. Hersh, D. Demeo, J. Reilly, E. Silverman (2007)
Xenobiotic metabolizing enzyme gene polymorphisms predict response to lung volume reduction surgeryRespiratory Research, 8
A. Buist (2002)
Guidelines for the management of chronic obstructive pulmonary disease.Respiratory medicine, 96 Suppl C
W MacNee, BR Celli (2004)
Diagnosis and treatment of patients with COPDEur Respir J, 23
C. Hassett, Lauri Aicher, J. Sidhu, C. Omiecinski (1994)
Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants.Human molecular genetics, 3 3
(2009)
Global strategy for the chronic obstructive pulmonary diagnosis, management, and prevention of disease.www.goldcopd.org
A. Medford (2004)
British Thoracic Society, 31
K. Rabe, S. Hurd, A. Anzueto, P. Barnes, Sonia Buist, P. Calverley, Yoshinosuke Fukuchi, C. Jenkins, R. Rodríguez-Roisín, C. Weel, Jan Zieliński (2007)
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.American journal of respiratory and critical care medicine, 176 6
(1997)
Cigarette smoke extracts inhibit plasma PON1 activity by modification of the enzyme’s free thiols
(2008)
Antioxidants therapiotic advances
PN Durrington, B Mackness, MI Mackness (2001)
Review: paraoxonase and atherosclerosisArterioscler Thromb Vasc Biol, 21
A Penyige, S Poliska, E Csanky, B Scholtz, B Dezso, I Schmellczer, L Kilty, L Takacs, L Nagy (2010)
Analysis of association between PPAR gamma and EPHX1polymorphisms and susceptibility to COPD in a Hungarian cohort, a case–control studyMed Genet, 11
(2007)
Accuracy and biological variation of human serum PON1 activity by enzymatic enzyme assay
S. Jindal, A. Aggarwal, K. Chaudhry, S. Chhabra, G. D'Souza, D. Gupta, Katiyar Sk, Rajesh Kumar, B. Shah, Vijayan Vk (2006)
A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure.The Indian journal of chest diseases & allied sciences, 48 1
CE Cross, A Vliet, CA O’Neill (2000)
Oxidants antioxidants and respiratory tract lining fluidsChest J, 117
(2001)
Interaction between Gln-Arg 192 variants of PON1 gene and oleic acid intake as determinant of HDL and PON1 activity
A. Sandford, T. Chagani, T. Weir, J. Connett, N. Anthonisen, P. Paré (2001)
Susceptibility genes for rapid decline of lung function in the lung health study.American journal of respiratory and critical care medicine, 163 2
CP Hersh, DL Demeo, R Lazarus, JC Celedón, BA Raby, JO Benditt, G Criner, B Make, FJ Martinez, PD Scanlon, FC Sciurba, JP Utz, JJ Reilly, EK Silverman (2006)
Genetic association analysis of functional impairment in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med, 173
M. Pearson (1999)
Guidelines for the management of chronic obstructive pulmonary disease.Caribbean health, 1 4
Norman Rizk, John Faul (2000)
Diagnosis and natural history of pulmonary infections in transplant recipients.Chest, 117 2
MI Mackness, B Mackness, PN Durrington, AM Fogelman, J Berliner, AJ Lusis, M Navab, D Shih, GC Fonarow (1998)
Paraoxonase and coronary heart diseaseCurr Opin Lipidol, 9
S. Chappell, L. Daly, K. Morgan, Tamar Guetta‐Baranés, J. Roca, R. Rabinovich, J. Lotya, A. Millar, S. Donnelly, Vera Keatings, W. Macnee, J. Stolk, P. Hiemstra, M. Miniati, S. Monti, C. O'connor, N. Kalsheker (2008)
Genetic variants of microsomal epoxide hydrolase and glutamate-cysteine ligase in COPDEuropean Respiratory Journal, 32
I. Rahman (2008)
Review: Antioxidant therapeutic advances in COPDTherapeutic Advances in Respiratory Disease, 2
A. Penyige, S. Póliska, E. Csánky, B. Scholtz, B. Dezső, I. Schmelczer, I. Kilty, L. Takacs, L. Nagy (2010)
Analyses of association between PPAR gamma and EPHX1 polymorphisms and susceptibility to COPD in a Hungarian cohort, a case-control studyBMC Medical Genetics, 11
C. Kiyohara, K. Yoshimasu, K. Takayama, Y. Nakanishi (2006)
EPHX1 Polymorphisms and the Risk of Lung Cancer: A HuGE ReviewEpidemiology, 17
M. Mackness, B. Mackness, P. Durrington (1998)
Paraoxonase and coronary heart disease.Atherosclerosis. Supplements, 3 4
Shirley Miller, D. Dykes, H. Polesky (1988)
A simple salting out procedure for extracting DNA from human nucleated cells.Nucleic acids research, 16 3
T. Tsao, J. Hong, L. Li, M. Hsieh, S. Liao, K. Chang (2000)
Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis.Chest, 117 1
(2000)
Guidelines for the management of chronic obstructive pulmonary diseaseChest J, 117
M. Sampson, S. Braschi, G. Willis, S. Astley (2005)
Paraoxonase-1 (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in Type II diabetes.Clinical science, 109 2
Xiao-rong Wang, E. Eisen, Hong-xi Zhang, Bi-Xiong Sun, He-lian Dai, Pan Ld, David Wegman, S. Olenchock, David Christiani (2003)
Respiratory symptoms and cotton dust exposure; results of a 15 year follow up observationOccupational and Environmental Medicine, 60
M. Tomás, Mariano Sentí, R. Elosua, Joan Vila, J. Sala, R. Masiá, J. Marrugat (2001)
Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity.European journal of pharmacology, 432 2-3
(2010)
COPD and PON1 192 and 55 gene polymorphisms
B. Isik, R. Işık, A. Ceylan, Orhan Calik (2005)
Trace elements and oxidative stress in chronic obstructive pulmonary disease.Saudi medical journal, 26 12
Jan Brøgger, Vidar Steen, H. Eiken, A. Gulsvik, Per Bakke (2006)
Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1European Respiratory Journal, 27
B. Isik, R. Işık, A. Ceylan, Orhan Calik (2005)
Trace elements and oxidative stress in COPD ...
S.-L. Cheng, C-J. Yu, C‐J. Chen, P. Yang (2004)
Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPDEuropean Respiratory Journal, 23
J. Maurer (2008)
Genetic Association Analysis of Functional Impairment in Chronic Obstructive Pulmonary DiseaseYearbook of Pulmonary Disease, 2008
G. Hu, Zhe Shi, Jinxing Hu, Guoming Zou, G. Peng, P. Ran (2008)
Association between polymorphisms of microsomal epoxide hydrolase and COPD: Results from meta‐analysesRespirology, 13
C. Mathers, Joshua Salomon, M. Ezzati, Stephen Begg, S. Hoorn, Alan Lopez (2006)
Sensitivity and Uncertainty Analyses for Burden of Disease and Risk Factor Estimates
(2005)
Para - oxonase 1 activity and protein thiol oxidation in sera of COPD patients
N. Ferré, J. Marsillach, J. Camps, B. Mackness, M. Mackness, F. Riu, B. Coll, M. Tous, J. Joven (2006)
Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases.Journal of hepatology, 45 1
L. Fromer, C. Cooper (2008)
A review of the GOLD guidelines for the diagnosis and treatment of patients with COPDInternational Journal of Clinical Practice, 62
(2000)
Role of oxidants/antioxidants in lung disease
S. Tekeş, B. Isik, T. Yıldız, S. Şimşek, M. Isik, T. Budak (2010)
Chronic Obstructive Pulmonary Disease and Paraoxonase-1 192 and 55 Gene PolymorphismsBiotechnology & Biotechnological Equipment, 24
B. Celli, W. Macnee, A. Agustí, A. Anzueto, B. Berg, A. Buist, P. Calverley, N. Chavannes, T. Dillard, B. Fahy, A. Fein, J. Heffner, S. Lareau, P. Meek, F. Martinez, W. McNicholas, J. Muris, E. Austegard, R. Pauwels, S. Rennard, A. Rossi, N. Siafakas, B. Tiep, J. Vestbo, E. Wouters, R. Zuwallack (2004)
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 23
P. Durrington, B. Mackness, M. Mackness (2001)
Paraoxonase and AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, 21
Oxidative stress is believed to play an important role in the pathogenesis of smoking-induced chronic obstructive pulmonary disease (COPD). We hypothesized that low serum activity level of paraoxonase-1 (PON1) that play a protective role in the lungs by metabolizing lipid peroxides and genetic polymorphism of antioxidant enzymes that detoxify cigarette smoke products such as microsomal epoxide hydroxylase-1 (m-EPHX-1) would be associated with increased susceptibility to COPD in smokers. The study was conducted on patients admitted to Chest Diseases Department, Kasr Al-Aini Hospital, Cairo University. Sixty subjects were divided into three groups—25 COPD patients, 25 chronic smokers without COPD, and 10 healthy nonsmokers. Pulmonary function tests were done for confirmation of COPD. Serum PON1 activity assay using spectrophotometric kinetic method and PCR-RFLP for genetic polymorphism of m-EPHX-1 exon 3 113 T>C were done to all participants. The significantly low median value for serum PON1 activity was found in COPD and smoker groups compared to the nonsmoker group (P = 0.015). Homozygote mutant genotype (HH) of m-EPHX-1 was present only in the COPD group compared to the other two groups with a frequency of 20%, 0%, and 0% respectively [P = 0.013; odds ratio (OR), 4.26; P = 0.008]. The OR between COPD and nonsmoker group was 14.222 (P = 0.008). The frequency of TH genotype was highest in the COPD group (44%, P = 0.013). While the wild genotype (TT) was more frequent in the nonsmoker group compared to the smokers and COPD groups (80%, 64%, and 36% respectively; P = 0.013). The slow m-EPHX-1 exon 3 polymorphisms (HH and HT) and the reduced serum PON1 activity are associated with higher susceptibility to COPD in smokers.
Comparative Clinical Pathology – Springer Journals
Published: Jan 28, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.